LMNA and Hutchinson-Gilford progeria syndrome: In addition, extending to non-oncological indications, lonafarnib was recently approved for the use in the rare pediatric premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS) to prevent farnesylation of mutant lamin A/C gene (LMNA).14